Download pptx - Ppt on Biocon

Transcript
Page 1: Ppt on Biocon

Submitted By:-Aparna VyasBarun KumarJayshree BhartiManoj DubeyRajesh KumarSaurabh MehtaManoj DubeyVeeresh Tripathi

Page 2: Ppt on Biocon

GLOBAL BIOTECHNOLOGY INDUSTRY

Discovery of Recombinant DNA technology in 1973.

Application in Agriculture, Industry, Medicine It is estimated that by 2025, BIO-DRUGS would

replace 70% of conventional Therapies. The global biotech industry was $84.6 billion in

2010 and is expected to grow at a 7% CAGR to $103 billion by 2013.

Page 3: Ppt on Biocon

Top 10 Global Biotech Corporations, 2010In terms of Revenue

Ranking Corporation

1 Roche

2 Amgen Inc

3 Gilead Sciences Inc

4 Biogen Idec Inc.

5 UCB SA

6 Genzyme Corp

7 CSL Ltd.

8 Celgene Corp

9 Cephalon Inc.

10 Actelion Ltd

Source : www.pharmalive.com

Page 4: Ppt on Biocon

INDIAN BIOTECHNOLOGY INDUSTRY Indian biotechnology industry revenues

touched Rs 15,000 crores in 2010-2011. The industry has grown consistently in

double digits over the last decade with average revenue growth figures greater than 20%.

It is estimated to reach a turnover of around Rs 45,000 crores by 2015

Source - The Biospectrum-ABLE industry survey 2011

Page 5: Ppt on Biocon

9th BioSpectrum-ABLE listing of Top 20 BioTech Companies 2010-11

Rank Company Revenue Change over2009-10 (%)

2010-11 2011 (%)1 Biocon 1483 25.682 Serum Institute of India 1041 22.473 Panacea Biotec 928.41 32.054 Nuziveedu Seeds 610 27.925 Reliance Life Sciences* 490 8.896 Quintiles India* 476.25 277 NovoNordisk 462 27.628 Rasi Seeds 371.88 3.659 Mahyco* 364.9 16.96

10 Transasia 350 88.1711 Ankur Seeds 325 196.812 Syngene International 318 26.1913 Bharat Biotech * 298.34 9.8214 Indian Immunologicals 283 3.7615 Krishidhan Seeds 276.13 107.2616 Shantha Biotech* 272 -18.6217 Novozymes South Asia * 242 8.0418 Bharat Serums 226 29.1419 Jubilant Life Sciences 210 -15.7620 Eli Lilly 204 9.25

Notes: * represents BioSpectrum estimates

Page 6: Ppt on Biocon

BIOCON – THE JOURNEY BEGINS Collaboration between Irish firm

Biocon International and kiran with kiran owning 70% equity.

Started Biocon India in 1978 from her garage with initial capital of Rs. 10000.

During next 15 years focused on Solid State Fermentation.

Biocon Secured a US Patent for reactor know as Plafactor for the manufacture of drugs.

Page 7: Ppt on Biocon

VISION AND MISSION

To promote social and economic inclusion by ensuring that marginalized communities have equal access to healthcare services.

Mission

Vision

To be an integrated biotechnology enterprise of global distinction.

Page 8: Ppt on Biocon

BIOCON AND ITS SUBSIDIARIES

Page 9: Ppt on Biocon

DR. KIRAN MAZUMDAR SHAW - ENTREPRENEUR

Visionary Innovative Leadership skills Risk averse Market analyst Self confident and

optimist

Page 10: Ppt on Biocon

DR. KIRAN MAZUMDAR SHAW - ENTREPRENEUR

Kiran Mazumdar-Shaw's pioneering efforts in biotechnology have drawn global recognition both for Indian Industry and Biocon.

Her unique vision has steered Biocon's transition from an industrial enzymes company to an integrated biopharmaceutical company with strategic research initiatives.

Ms. Shaw is the recipient of several prestigious awards including Best Woman Entrepreneur, Model Employer, Ernst & Young's Entrepreneur of the Year Award for Life Sciences & Healthcare, Leading Exporter, Outstanding Citizen, Technology Pioneer, etc.

Her most cherished award is however, the PADMASHRI (1989) presented to her by the then President of India, for her pioneering efforts in Industrial Biotechnology.

Page 11: Ppt on Biocon

FEW MILESTONES ACHIEVED BY BIOCON

1978 - Incorporated as JV-Biocon Biochemicals Ltd & Kiran Mazumdar-Shaw. 1979 - First Indian company to manufacture and export enzymes to USA and

Europe. 1996 - The commercial success of Biocon's proprietary fermentation plant leads

to a 3-fold expansion; enters biopharmaceuticals and statins. 1998 - Unilever agrees to sell its shareholding in Biocon to the Indian promoters.

Biocon becomes an independent entity 2000 - Establishes Clinigene, India's first Clinical Research Organisation (CRO). 2003 –First company worldwide to develop human insulin (Pichia expression

system). 2006 - Inaugurates Biocon Biopharmaceuticals, India's largest multi-product

Biologics facility ; India's first anti-cancer drug, BIOMAb EGFR®. 2008 - Biocon acquires 70% stake in German pharmaceutical company, AxiCorp

GmbH 2009 - Biocon launches BASALOGTM - long lasting basal insulin for Type 1 &

Type 2 Diabetics.

Page 12: Ppt on Biocon

COMPETITORS Wockhardt Limited Sun Pharmaceutical Industries Limited Ranbaxy Laboratories Limited Bharat Biotech International Limited Dr. Reddy's Laboratories Limited Oramed Pharmaceuticals, Inc.

Page 13: Ppt on Biocon

PRODUCTS & SERVICES

ENZYMES

BIOPHARMACEUTICALS

CLINICAL RESEARCH

CUSTOM RESEARCH

Small Molecules Biologicals Dosage Forms

BIOCON

Page 14: Ppt on Biocon

SWOT ANALYSIS

Internal Strengths

Biocon’s strength lies in consolidated skills in producing enzymes. Another Biocon’s strength lies in its de-risked business model. Biocon is US FDA Certified Company which gives it a wide scope to

enter global markets. This company is also the market Leader in India which becomes its

one of the major strengths. Its core competence in molecular biology is one of the strengths it

has. Internal low cost of clinical research gives it the power to stand

and fight with all the competitors in the market. Last but not the least development of Oral Insulin is also one of its

major strengths.

Page 15: Ppt on Biocon

SWOT ANALYSIS

Internal Weaknesses

80% of Biocon’s turnover comes from Statins which also makes 45% of its revenues.

Biocon’s another major weakness lies because of its capacity build up in CRO.

Moreover it also has the least expertise in final stage which is very important.

Its marketing activities have been poor due to investments in other  activities of the company

Page 16: Ppt on Biocon

SWOT ANALYSIS

External Opportunity

$82 billion worth global b”busters facing patent expiry India Share of Global generic market  Increased  to

33% from 4 % Enzymes market growing at 6.5 % Outsourcing to reduce cost India preferred destination for clinical trails  ( $70

million – 20% Gr) 177 Mn ( G )/ 45 Mn (I) Diabetic Patients 9 million cancer cases Entry of venture capitalist.

Page 17: Ppt on Biocon

SWOT ANALYSIS

External Threats

Risk  in drug discovery Generics Market Being over crowded Strict IP regulatory laws Low cost Chinese Competitors Intense Competion in CRO

Page 18: Ppt on Biocon

PEST ANALYSIS

Political Factors 

•The Minister in charge of the industry has been threatening to impose even morestringent Price Control on the industry than before.•Effective January, 2005 the country goes in for the IPR (Intellectual Property Rights)regime, popularly known as the Patent Act. This Act will impact the PharmaceuticalIndustry the most. •In Pharma industry there is a huge PSU segment which is chronically sick and highlyinefficient. •.Effective the January, 2005 the Government has shifted from charging the ExciseDuty on the cost of manufacturing to the MRP thereby making the finished productsmore costly

Page 19: Ppt on Biocon

PEST ANALYSIS

Economic Factors  India spends a very small proportion of its

GDP on healthcare ( A mere 1% ). Thishas stunted the demand and therefore the growth of the industry.

Per capita income of an average Indian is low ( Rs. 12,890 ), therefore, spending onthe healthcare takes a low priority.

The incidence of Taxes are very high

Page 20: Ppt on Biocon

PEST ANALYSIS

Socio-cultural Factors  Poverty and associated malnutrition dramatically

exacerbate the incidence of Malaria and TB, preventable diseases that continue to play havoc in India decadesafter they were eradicated in other countries.

Poor Sanitation and polluted water sources prematurely end the life of about 1million children under the age of five every year.

Large joint families transmit communicable diseases amongst the members

Cattle-rearing encourage diseases communicated by animals.

Page 21: Ppt on Biocon

PEST ANALYSIS

Technological Factors  Advanced automated machines have increased

the output and reduced the cost. Computerization has increased the

efficiency of the Pharma Industry. Advances in Bio-technology, Stem-cell research

have given India a step forward. Newer drug delivery systems are the

innovations of the day

Page 22: Ppt on Biocon

STRATEGY Diversification rather than Expansion – Sequential

Growth Strategy – Adding interlinked Business. Strategic alliances with Global Biotech firms as a way

of Sharing development cost. PFIZER – 2011 OPTIMER – 2011 NOBEX CORP USA

Focusing on Molecular Biology - Fermentation rather than Synthetic Chemistry to differentiate itself from competitors.

Using Generics Platform to move into Drug Discovery.

Page 23: Ppt on Biocon

STRATEGY Innovation – Led Strategy

Page 24: Ppt on Biocon

STRATEGY

Split Business Technique

SyngeneClinigeneBiocon

Page 25: Ppt on Biocon

MARKET ANALYSIS

Page 26: Ppt on Biocon

FINANCIAL ANALYSIS

Page 27: Ppt on Biocon

FINANCIAL ANALYSIS

Page 28: Ppt on Biocon

FINANCIAL ANALYSIS

Page 29: Ppt on Biocon

FINANCIAL ANALYSIS

Page 30: Ppt on Biocon

FINANCIAL ANALYSIS

Page 31: Ppt on Biocon

FINANCIAL ANALYSIS

Biocon’s net sales grew by 17% to 13,250,660 in 2010-11. Company’s domestic revenues from product sales have increased by 25%, and exports sales have increased by 8%.

The current assets, loans and advances have increased by 18% over the previous year.

The current ratio have increased by 8.5% over the previous year.

Page 32: Ppt on Biocon

ENZYMES BIO-PHARMACEUTICAL

CLINIC RESEARCH CUSTOM RESEARCH

ENZYMES BIO-PHARMACEUTICAL

CUSTOM RESEARCH

CLINIC RESEARCH

BCG ANALYSIS

Page 33: Ppt on Biocon

CONCLUSION On the manufacturing front, the innovation efforts

should be directed towards delivering the highest quality at the lowest cost.

On the services front, Syngene and Clinigene must aim to compete by augmenting specialized skills to deliver increasingly higher value services in a cost effective manner.

On the research front, Biocon should pursue a strategy that will deliver incremental and transformational innovation in an affordable manner.

Underlying these efforts there must be an un-flinching commitment to operational excellence which is now a prerequisite for global competitiveness.

Page 34: Ppt on Biocon

THANK YOU